- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Mi | bioAffinity Technologies regains Nasdaq compliance; shares surge | 2 | Seeking Alpha | ||
| Mi | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Morning Market Movers: Focus Universal, CEA Industries, bioAffinity Technologies, Dyne Therapeutics See Big Swings | 602 | AFX News | OTTAWA (dpa-AFX) - At 8:55 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 05.09. | bioAffinity's AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? | 15 | Insider Monkey | ||
| 03.09. | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | 646 | AFX News | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 03.09. | bioAffinity Technologies: Aktie schießt nach Erweiterung des Marktpotenzials für Lungenkrebstest in die Höhe | 8 | Investing.com Deutsch | ||
| 02.09. | 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | 726 | AFX News | BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies... ► Artikel lesen | |
| 20.08. | bioAffinity Technologies announces 1-for-15 reverse stock split | 17 | Seeking Alpha | ||
| 20.08. | bioAffinity Technologies führt Aktienzusammenlegung im Verhältnis 1:15 durch | 5 | Investing.com Deutsch | ||
| 20.08. | bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 | 385 | Business Wire | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced... ► Artikel lesen | |
| 18.08. | bioAffinity partners with AvMEDICAL for VA distribution | 5 | Investing.com | ||
| 18.08. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | bioAffinity Technologies sichert sich 4 Mio. US-Dollar durch Privatplatzierung | 2 | Investing.com Deutsch | ||
| 14.08. | bioAffinity Technologies closes $4M private placement | 1 | Investing.com | ||
| 13.08. | bioAffinity Technologies prices $4M private placement | 3 | Seeking Alpha | ||
| 07.08. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 31.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | bioAffinity und Pictor kooperieren bei Entwicklung von Tests für Asthma und COPD | 2 | Investing.com Deutsch | ||
| 22.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | bioAffinity partners with Pictor on asthma, COPD tests | 1 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,490 | +2,47 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| BIONXT SOLUTIONS | 0,210 | 0,00 % | BioNxt treibt die Entwicklung eines sublingualen Everolimus-ODF gegen Organabstoßung durch den Start einer pharmakokinetischen Studie an Großtieren voran | VANCOUVER, BC / ACCESS Newswire /
8. September 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT) (OTCQB:BNXTF) (FWB:BXT), ein innovatives
Biowissenschaftsunternehmen... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,115 | 0,00 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,340 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,252 | -11,27 % | Onco-Innovations Limited: Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species | ||
| TRAWS PHARMA | 0,520 | +0,19 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| CURIS | 0,959 | 0,00 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYBIN | 11,600 | -1,53 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| GENPREX | 3,350 | -2,90 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| TVARDI THERAPEUTICS | 1,430 | -7,74 % | Lucid Capital Markets initiates Tvardi stock with buy rating | ||
| NEOVACS | 0,310 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 1,490 | +2,05 % | Alaunos Therapeutics, Inc.: Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight... ► Artikel lesen | |
| BIOLINERX | 1,850 | -10,19 % | BioLineRx, Hemispherian to present GLIX1 data at EANO meeting | ||
| BIOARCTIC | 28,280 | -2,28 % | BioArctic: Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi | STOCKHOLM, Sept. 1, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting... ► Artikel lesen |
BIOAFFINITY TECHNOLOGIES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -22,45 % bei einem Aktienkurs von 6,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.